Melanocortin 1 receptor selective compounds
CA 2327550 A1 · Owner: Mutulis, Felikss · Inventors: Mutulis, Felikss; Wikberg, Jarl; Muceniece, Ruta
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound of general formula (1) wherein R1 R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are H or methyl R13, R14, R15 and R16 are H or alkyl, wherein L1 and L2 are linkers selected from single bond methyl, ethyl, wherein R19, R20 and R21 are H or -CH2X NT is selected from H, hydroxyl, alkyl aminoacid, aminoacid analogue, polypeptide and functional group CT is , selected from hydrogen, hydroxyl alkyl, aminoacid, aminoacid analogue, polypeptide and functional group shows high selectivity and high affinity for MC1-receptors in combination with effective stimulation or inhibiton of cAMP formation in MC1-receptor expressing cells but low affinity for other subtypes of MC-receptors and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 5, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 5, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 5, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.